百诚医药
(301096)
| 流通市值：53.53亿 | | | 总市值：70.36亿 |
| 流通股本：8309.00万 | | | 总股本：1.09亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 160,457,682.24 | 677,987,094.68 | 509,883,681.59 | 332,353,112.78 |
| 营业收入 | 160,457,682.24 | 677,987,094.68 | 509,883,681.59 | 332,353,112.78 |
| 二、营业总成本 | 151,266,524.68 | 748,339,939.83 | 508,846,004.57 | 336,557,099.34 |
| 营业成本 | 79,423,680.98 | 410,161,147.68 | 260,154,332.01 | 163,735,104.78 |
| 税金及附加 | 2,542,880.55 | 5,162,381.38 | 7,035,769.93 | 4,632,301.02 |
| 销售费用 | 2,478,164.33 | 10,187,254.65 | 7,446,866.95 | 5,720,791.43 |
| 管理费用 | 28,310,891.86 | 114,929,455 | 82,332,695.29 | 53,967,967.42 |
| 研发费用 | 33,597,059.38 | 189,867,051.66 | 139,288,938.29 | 100,966,474.15 |
| 财务费用 | 4,913,847.58 | 18,032,649.46 | 12,587,402.1 | 7,534,460.54 |
| 其中:利息费用 | 5,539,876.81 | 21,169,546.31 | 15,407,766.14 | 9,591,444.49 |
| 其中:利息收入 | 347,008.57 | 3,207,729.02 | 2,987,138.11 | 2,161,769.83 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 268,053.63 | -11,796,809.44 | 2,668,835.48 | 1,688,430.57 |
| 资产处置收益 | - | 218,302.93 | - | - |
| 资产减值损失(新) | 70,567.42 | -9,063,708.45 | -2,646,037.48 | 937,128.96 |
| 信用减值损失(新) | -2,247,177.33 | -24,621,259.73 | -10,476,858.77 | -7,665,710.17 |
| 其他收益 | 4,914,316.37 | 26,581,670.67 | 17,066,545.36 | 12,929,850.36 |
| 四、营业利润 | 12,196,917.65 | -89,034,649.17 | 7,650,161.61 | 3,685,713.16 |
| 加:营业外收入 | 117,257.08 | 733,577.17 | 721,464.34 | 240,566.96 |
| 减:营业外支出 | 66,702.08 | 2,837,892.38 | 406,566.89 | 25,794.03 |
| 五、利润总额 | 12,247,472.65 | -91,138,964.38 | 7,965,059.06 | 3,900,486.09 |
| 减:所得税费用 | -564,985.77 | -743,434.3 | 1,840,849.1 | 802,325.55 |
| 六、净利润 | 12,812,458.42 | -90,395,530.08 | 6,124,209.96 | 3,098,160.54 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 12,812,458.42 | -90,395,530.08 | 6,124,209.96 | 3,098,160.54 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,812,458.42 | -90,395,530.08 | 6,124,209.96 | 3,098,160.54 |
| 少数股东损益 | - | - | 0 | 0 |
| 扣除非经常损益后的净利润 | 7,698,808.5 | -103,106,780.25 | -13,917,309.19 | -11,730,144.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | -0.83 | 0.06 | 0.03 |
| (二)稀释每股收益 | 0.12 | -0.83 | 0.06 | 0.03 |
| 八、其他综合收益 | 11,144 | -40,484.38 | -42,606.52 | -30,111.11 |
| 归属于母公司股东的其他综合收益 | 11,144 | -40,484.38 | -42,606.52 | -30,111.11 |
| 九、综合收益总额 | 12,823,602.42 | -90,436,014.46 | 6,081,603.44 | 3,068,049.43 |
| 归属于母公司股东的综合收益总额 | 12,823,602.42 | -90,436,014.46 | 6,081,603.44 | 3,068,049.43 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-25 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |